UAE approves use of Sinopharm vaccine for children aged between 3 and 17 years
ABU DHABI: The UAE Ministry of Health has approved the use of the Sinopharm vaccine against COVID-19 for children in the 3-17 years age group in UAE.
This was announced by the UAE Ministry of Health and Prevention in a tweet today.
With this decision, UAE will be able to further ramp up its fight against the COVID-19 pandemic.
This decision to approve Sinopharm vaccine for children 3-17 years old has been taken based on the results of clinical studies, the strict assessment to approve the emergency use of the vaccine and the local evaluation that complies with the approved regulations.
Abu Dhabi’s health regulator, the Department of Health (DoH) announced on Sunday the successful completion of the Sinopharm bridge study, carried out under the supervision of MoHAP, and in collaboration with the Abu Dabi Health Services Company (Seha), the emirate’s public health provider.
The study had enrolled, with full parental consent, a total of 900 children aged between three and 17 years old. It was launched in June (2021), and was the first project in the Middle East and North Africa region designed to study young children’s immune response to being inoculated against COVID-19. Children of different nationalities were enrolled, administered Sinopharm vaccine doses, and closely monitored over the following weeks.
The DoH referred to the participating children and their families as ‘heroes’ in the UAE’s fight against the COVID-19 pandemic.
The roll-out of the vaccine for this age group in the UAE is likely to support a safer return to school for many children in September, especially as COVID-19 variants increase infection rates worldwide. Till date, the UAE had provided Pfizer COVID-19 vaccines to only children aged 12 years and older, and this will therefore be the first chance for residents to vaccinate younger children against COVID-19.
- GULF NEWS
source http://www.dailynews.lk/2021/08/04/world/255636/uae-approves-use-sinopharm-vaccine-children-aged-between-3-and-17-years
No comments